T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Google Secures Pentagon AI Deal for Classified Projects 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
MENLO PARK, Calif., Feb. 17, 2016 -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the fourth quarter and year ended December 31, 2015, on Thursday, February 25, 2016, after the market close. Geron’s management will also host a conference call for analysts and investors on Thursday, February 25, 2016, at 4:30 p.m. Eastern Time to discuss the company’s fourth quarter and annual results and events.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 48851221. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at http://edge.media-server.com/m/p/txcpdjvg. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through March 26, 2016.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
